ORIX Corp. on Pace for Largest Percent Increase Since January 2023 — Data Talk
ORIX Corporation Sponsored ADR (IX) is currently at $97.09, up $3.79 or 4.06%
--Would be highest close since Sept. 25, 2023, when it closed at $97.33
--On pace for largest percent increase since Jan. 17, 2023, when it rose 4.24%
--Currently up two consecutive days; up 5.43% over this period
--Best two day stretch since the two days ending Nov. 11, 2022, when it rose 8.56%
--Down 39.33% from its all-time closing high of $160.03 on April 4, 2006
--Up 20.18% from 52 weeks ago (Jan. 6, 2023), when it closed at $80.79
--Down 4.24% from its 52-week closing high of $101.39 on Sept. 19, 2023
--Up 21.71% from its 52-week closing low of $79.77 on Jan. 10, 2023
--Traded as high as $97.81; highest intraday level since Sept. 27, 2023, when it hit $98.15
--Up 4.83% at today's intraday high; largest intraday percent increase since Nov. 10, 2022, when it rose as much as 5.64%
All data as of 1:42:57 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
January 05, 2024 14:02 ET (19:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track